1 day Ago By ABMN Staff
Virtu Financial LLC purchased a new position in Nautilus Biotechnology, Inc. ( NASDAQ:NAUT – Free Report ) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 16,604 shares of the company’s stock, valued at approximately $28,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC boosted its holdings in shares of Nautilus Biotechnology by 56.3% in the 4th quarter.
SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after purchasing an additional 9,904 shares during the period. Palumbo Wealth Management LLC boosted its stake in Nautilus Biotechnology by 45.4% during the fourth quarter.
Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock worth $48,000 after buying an additional 8,888 shares during the period. The Manufacturers Life Insurance Company bought a new position in Nautilus Biotechnology during the third quarter valued at $67,000. MetLife Investment Management LLC purchased a new stake in shares of Nautilus Biotechnology in the third quarter valued at $87,000.
Finally, Barclays PLC lifted its holdings in shares of Nautilus Biotechnology by 79.6% in the 3rd quarter. Barclays PLC now owns 106,174 shares of the company’s stock worth $303,000 after acquiring an additional 47,059 shares during the last quarter.
50.71% of the stock is currently owned by hedge funds and other institutional investors. Nautilus Biotechnology Price Performance Nautilus Biotechnology stock opened at $0.
83 on Wednesday. The stock has a market cap of $104.72 million, a price-to-earnings ratio of -1.
48 and a beta of 1.25. The firm has a 50-day moving average of $1.
40 and a two-hundred day moving average of $2.02. Nautilus Biotechnology, Inc.
has a 1 year low of $0.82 and a 1 year high of $3.09.
Insider Activity Analyst Ratings Changes NAUT has been the topic of several analyst reports. Guggenheim set a $2.50 price target on shares of Nautilus Biotechnology in a report on Friday, February 28th.
The Goldman Sachs Group downgraded Nautilus Biotechnology from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $2.25 to $1.75 in a report on Thursday, December 5th.
View Our Latest Report on Nautilus Biotechnology Nautilus Biotechnology Company Profile ( Free Report ) Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. Further Reading Want to see what other hedge funds are holding NAUT? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Nautilus Biotechnology, Inc. ( NASDAQ:NAUT – Free Report ). Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.
com's FREE daily email newsletter ..
_8.jpg?itok=wp-xhXRB)
